{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T10:45:38Z","timestamp":1788864338780,"version":"build-2803163510"},"reference-count":47,"publisher":"The Endocrine Society","issue":"5","license":[{"start":{"date-parts":[[2023,4,4]],"date-time":"2023-04-04T00:00:00Z","timestamp":1680566400000},"content-version":"vor","delay-in-days":29,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"Takeda Pharmaceuticals USA, Inc."}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,3,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Context<\/jats:title>\n                  <jats:p>Chronic hypoparathyroidism is conventionally treated with oral calcium and active vitamin D to reach and maintain targeted serum calcium and phosphorus levels, but some patients remain inadequately controlled.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Objective<\/jats:title>\n                  <jats:p>To assess long-term safety and efficacy of recombinant human parathyroid hormone (1-84) (rhPTH(1-84)) treatment.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>This was an open-label extension study at 12 US centers. Adults (n = 49) with chronic hypoparathyroidism were included. The intervention was rhPTH(1-84) for 6 years. The main outcome measures were safety, biochemical measures, oral supplement doses, bone indices.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Thirty-eight patients (77.6%) completed the study. Throughout 72 months, mean albumin-adjusted serum calcium was within 2.00 to 2.25\u2005mmol\/L (8.0-9.0\u2005mg\/dL). At baseline, 65% of patients with measurements (n = 24\/37) were hypercalciuric; of these, 54% (n = 13\/24) were normocalciuric at month 72. Mean serum phosphorus declined from 1.6 \u00b1 0.19\u2005mmol\/L at baseline (n = 49) to 1.3 \u00b1 0.20\u2005mmol\/L at month 72 (n = 36). Mean estimated glomerular filtration rate was stable. rhPTH(1-84)-related adverse events were reported in 51.0% of patients (n = 25\/49); all but 1 event were mild\/moderate in severity. Mean oral calcium supplementation reduced by 45% \u00b1 113.6% and calcitriol by 74% \u00b1 39.3%. Bone turnover markers declined by month 32 to a plateau above pretreatment values; only aminoterminal propeptide of type 1 collagen remained outside the reference range. Mean bone mineral density z score fell at one-third radius and was stable at other sites.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>6 years of rhPTH(1-84) treatment was associated with sustained improvements in biochemical parameters, a reduction in the percentage of patients with hypercalciuria, stable renal function, and decreased supplement requirements. rhPTH(1-84) was well tolerated; no new safety signals were identified.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1210\/jendso\/bvad043","type":"journal-article","created":{"date-parts":[[2023,4,4]],"date-time":"2023-04-04T18:23:48Z","timestamp":1680632628000},"source":"Crossref","is-referenced-by-count":9,"title":["Long-Term Safety and Efficacy of Recombinant Human Parathyroid Hormone (1-84) in Adults With Chronic Hypoparathyroidism"],"prefix":"10.1210","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0719-9801","authenticated-orcid":false,"given":"Nelson B","family":"Watts","sequence":"first","affiliation":[{"name":"Osteoporosis and Bone Health Services, Mercy Health , Cincinnati, OH 45236 , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1570-2617","authenticated-orcid":false,"given":"John P","family":"Bilezikian","sequence":"additional","affiliation":[{"name":"Division of Endocrinology, Vagelos College of Physicians and Surgeons, Columbia University , New York, NY 10032 , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4227-2595","authenticated-orcid":false,"given":"Henry G","family":"Bone","sequence":"additional","affiliation":[{"name":"Michigan Bone and Mineral Clinic, PC , Detroit, MI 48236 , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3801-9546","authenticated-orcid":false,"given":"Bart L","family":"Clarke","sequence":"additional","affiliation":[{"name":"Division of Endocrinology, Diabetes, Metabolism, and Nutrition, Mayo Clinic , Rochester, MN 55905 , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3466-1208","authenticated-orcid":false,"given":"Douglas","family":"Denham","sequence":"additional","affiliation":[{"name":"Clinical Trials of Texas, Inc. , San Antonio, TX 78229 , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0036-7809","authenticated-orcid":false,"given":"Michael A","family":"Levine","sequence":"additional","affiliation":[{"name":"Division of Endocrinology and Diabetes and Center for Bone Health, Children's Hospital of Philadelphia , Philadelphia, PA 19104 , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0867-9778","authenticated-orcid":false,"given":"Michael","family":"Mannstadt","sequence":"additional","affiliation":[{"name":"Endocrine Unit, Massachusetts General Hospital and Harvard Medical School , Boston, MA 02114 , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2947-7147","authenticated-orcid":false,"given":"Munro","family":"Peacock","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Endocrinology, Indiana University School of Medicine , Indianapolis, IN 46202 , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5185-6648","authenticated-orcid":false,"given":"Jeffrey G","family":"Rothman","sequence":"additional","affiliation":[{"name":"UPG-Endocrine (Research Division) , Staten Island, NY 10301 , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1628-9673","authenticated-orcid":false,"given":"Tamara J","family":"Vokes","sequence":"additional","affiliation":[{"name":"Section of Endocrinology, University of Chicago Medicine , Chicago, IL 60637 , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6693-9860","authenticated-orcid":false,"given":"Mark L","family":"Warren","sequence":"additional","affiliation":[{"name":"Endocrinology and Metabolism, Physicians East, PA , Greenville, NC 27834 , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaoming","family":"Yin","sequence":"additional","affiliation":[{"name":"Takeda Pharmaceuticals USA, Inc. , Lexington, MA 02421 , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Sherry","sequence":"additional","affiliation":[{"name":"Takeda Pharmaceuticals USA, Inc. , Lexington, MA 02421 , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2936-4468","authenticated-orcid":false,"given":"Dolores M","family":"Shoback","sequence":"additional","affiliation":[{"name":"Endocrine Research Unit, San Francisco Veterans Affairs Medical Center , San Francisco, CA 94121 , USA"},{"name":"Department of Medicine, University of California , San Francisco, CA 94143 , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","published-online":{"date-parts":[[2023,4,4]]},"reference":[{"issue":"6","key":"2023042108445330200_bvad043-B1","doi-asserted-by":"crossref","first-page":"1722","DOI":"10.1210\/clinem\/dgaa113","article-title":"Hypoparathyroidism","volume":"105","author":"Bilezikian","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"2023042108445330200_bvad043-B2","doi-asserted-by":"crossref","first-page":"2313","DOI":"10.1210\/jc.2015-3910","article-title":"Management of hypoparathyroidism: present and future","volume":"101","author":"Bilezikian","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"2023042108445330200_bvad043-B3","doi-asserted-by":"crossref","first-page":"2300","DOI":"10.1210\/jc.2015-3909","article-title":"Presentation of hypoparathyroidism: etiologies and clinical features","volume":"101","author":"Shoback","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"2023042108445330200_bvad043-B4","doi-asserted-by":"crossref","first-page":"G1","DOI":"10.1530\/EJE-15-0628","article-title":"European Society of Endocrinology clinical guideline: treatment of chronic hypoparathyroidism in adults","volume":"173","author":"Bollerslev","year":"2015","journal-title":"Eur J Endocrinol"},{"issue":"6","key":"2023042108445330200_bvad043-B5","doi-asserted-by":"crossref","first-page":"2273","DOI":"10.1210\/jc.2015-3907","article-title":"Management of hypoparathyroidism: summary statement and guidelines","volume":"101","author":"Brandi","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"2023042108445330200_bvad043-B6","doi-asserted-by":"crossref","first-page":"R33","DOI":"10.1530\/EJE-21-1044","article-title":"European Expert consensus on practical management of specific aspects of parathyroid disorders in adults and in pregnancy: recommendations of the ESE educational program of parathyroid disorders","volume":"186","author":"Bollerslev","year":"2021","journal-title":"Eur J Endocrinol"},{"key":"2023042108445330200_bvad043-B7","doi-asserted-by":"crossref","first-page":"766","DOI":"10.12688\/f1000research.22717.1","article-title":"Recent advances in understanding and managing hypoparathyroidism","volume":"9","author":"Rubin","year":"2020","journal-title":"F1000Res"},{"issue":"4","key":"2023042108445330200_bvad043-B8","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1016\/j.ecl.2018.07.012","article-title":"Conventional treatment of hypoparathyroidism","volume":"47","author":"Babey","year":"2018","journal-title":"Endocrinol Metab Clin North Am"},{"issue":"4","key":"2023042108445330200_bvad043-B9","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1056\/NEJMcp0803050","article-title":"Hypoparathyroidism","volume":"359","author":"Shoback","year":"2008","journal-title":"N Engl J Med"},{"issue":"12","key":"2023042108445330200_bvad043-B10","doi-asserted-by":"crossref","first-page":"4507","DOI":"10.1210\/jc.2012-1808","article-title":"Long-term follow-up of patients with hypoparathyroidism","volume":"97","author":"Mitchell","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"2023042108445330200_bvad043-B11","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1002\/jbmr.3368","article-title":"Long-term complications in patients with hypoparathyroidism evaluated by biochemical findings: a case-control study","volume":"33","author":"Underbjerg","year":"2018","journal-title":"J Bone Miner Res"},{"key":"2023042108445330200_bvad043-B12","doi-asserted-by":"crossref","first-page":"172","DOI":"10.3389\/fendo.2016.00172","article-title":"Review of hypoparathyroidism","volume":"7","author":"Abate","year":"2017","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"2","key":"2023042108445330200_bvad043-B13","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1111\/j.1365-2265.2012.04353.x","article-title":"Prevalence and progression of basal ganglia calcification and its pathogenic mechanism in patients with idiopathic hypoparathyroidism","volume":"77","author":"Goswami","year":"2012","journal-title":"Clin Endocrinol"},{"issue":"1","key":"2023042108445330200_bvad043-B14","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1530\/EJE-18-0580","article-title":"Long-term complications in patients with chronic hypoparathyroidism: a cross-sectional study","volume":"180","author":"David","year":"2019","journal-title":"Eur J Endocrinol"},{"issue":"11","key":"2023042108445330200_bvad043-B15","doi-asserted-by":"crossref","first-page":"2277","DOI":"10.1002\/jbmr.1979","article-title":"Cardiovascular and renal complications to postsurgical hypoparathyroidism: a Danish nationwide controlled historic follow-up study","volume":"28","author":"Underbjerg","year":"2013","journal-title":"J Bone Miner Res"},{"issue":"5","key":"2023042108445330200_bvad043-B16","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0232842","article-title":"Prevalence and complications of nonsurgical hypoparathyroidism in Korea: a nationwide cohort study","volume":"15","author":"Kim","year":"2020","journal-title":"PLoS One"},{"issue":"10","key":"2023042108445330200_bvad043-B17","doi-asserted-by":"crossref","first-page":"2096","DOI":"10.1016\/j.clinthera.2017.08.011","article-title":"Safety and efficacy of recombinant human parathyroid hormone in adults with hypoparathyroidism randomly assigned to receive fixed 25-\u03bcg or 50-\u03bcg daily doses","volume":"39","author":"Bilezikian","year":"2017","journal-title":"Clin Therap"},{"issue":"4","key":"2023042108445330200_bvad043-B18","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/S2213-8587(13)70106-2","article-title":"Efficacy and safety of recombinant human parathyroid hormone (1-84) in hypoparathyroidism (REPLACE): a double-blind, placebo-controlled, randomized, phase 3 study","volume":"1","author":"Mannstadt","year":"2013","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"10","key":"2023042108445330200_bvad043-B19","doi-asserted-by":"crossref","first-page":"2358","DOI":"10.1002\/jbmr.470","article-title":"The effect of adding PTH(1-84) to conventional treatment of hypoparathyroidism: a randomized, placebo-controlled study","volume":"26","author":"Sikjaer","year":"2011","journal-title":"J Bone Miner Res"},{"issue":"11","key":"2023042108445330200_bvad043-B20","doi-asserted-by":"crossref","first-page":"5601","DOI":"10.1210\/jc.2019-00893","article-title":"Therapy of hypoparathyroidism with rhPTH(1-84): a prospective, 8\u2013year investigation of efficacy and safety","volume":"104","author":"Tay","year":"2019","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"2023042108445330200_bvad043-B21","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1007\/s12020-016-1141-0","article-title":"Effects of parathyroid hormone rhPTH(1-84) on phosphate homeostasis and vitamin D metabolism in hypoparathyroidism: REPLACE phase 3 study","volume":"55","author":"Clarke","year":"2017","journal-title":"Endocrine"},{"issue":"11","key":"2023042108445330200_bvad043-B22","doi-asserted-by":"crossref","first-page":"5136","DOI":"10.1210\/jc.2019-01010","article-title":"Safety and efficacy of 5 years of treatment with recombinant human parathyroid hormone in adults with hypoparathyroidism","volume":"104","author":"Mannstadt","year":"2019","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"2023042108445330200_bvad043-B23","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1210\/jc.2012-2984","article-title":"Therapy of hypoparathyroidism with PTH(1-84): a prospective four-year investigation of efficacy and safety","volume":"98","author":"Cusano","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"issue":"7","key":"2023042108445330200_bvad043-B24","doi-asserted-by":"crossref","first-page":"2742","DOI":"10.1210\/jc.2015-4135","article-title":"Therapy of hypoparathyroidism with PTH(1-84): a prospective six year investigation of efficacy and safety","volume":"101","author":"Rubin","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"issue":"9","key":"2023042108445330200_bvad043-B25","doi-asserted-by":"crossref","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","article-title":"A new equation to estimate glomerular filtration rate","volume":"150","author":"Levey","year":"2009","journal-title":"Ann Intern Med"},{"issue":"3","key":"2023042108445330200_bvad043-B26","doi-asserted-by":"crossref","first-page":"P1","DOI":"10.1530\/EJE-18-0609","article-title":"Standards of care for hypoparathyroidism in adults: a Canadian and international consensus","volume":"180","author":"Khan","year":"2019","journal-title":"Eur J Endocrinol"},{"issue":"9","key":"2023042108445330200_bvad043-B27","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.1002\/jbmr.2501","article-title":"The epidemiology of nonsurgical hypoparathyroidism in Denmark: a nationwide case finding study","volume":"30","author":"Underbjerg","year":"2015","journal-title":"J Bone Miner Res"},{"issue":"4","key":"2023042108445330200_bvad043-B28","doi-asserted-by":"crossref","first-page":"1876","DOI":"10.1007\/s12325-021-01658-1","article-title":"Risk of chronic kidney disease and estimated glomerular filtration rate decline in patients with chronic hypoparathyroidism: a retrospective cohort study","volume":"38","author":"Gosmanova","year":"2021","journal-title":"Adv Ther"},{"issue":"4","key":"2023042108445330200_bvad043-B29","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.1007\/s12325-021-01649-2","article-title":"Risk of nephrolithiasis and nephrocalcinosis in patients with chronic hypoparathyroidism: a retrospective cohort study","volume":"38","author":"Ketteler","year":"2021","journal-title":"Adv Ther"},{"issue":"2","key":"2023042108445330200_bvad043-B30","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1007\/s11154-020-09613-1","article-title":"Renal complications in patients with chronic hypoparathyroidism on conventional therapy: a systematic literature review: renal disease in chronic hypoparathyroidism","volume":"22","author":"Gosmanova","year":"2021","journal-title":"Rev Endocr Metab Disord"},{"issue":"2","key":"2023042108445330200_bvad043-B31","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1111\/cen.14470","article-title":"Determinants of hypercalciuria and renal calcifications in chronic hypoparathyroidism: a cross-sectional study","volume":"95","author":"Ridder","year":"2021","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"1","key":"2023042108445330200_bvad043-B32","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1007\/BF00294345","article-title":"Role of citric acid in primary hyperparathyroidism with renal lithiasis","volume":"20","author":"Alvarez-Arroyo","year":"1992","journal-title":"Urol Res"},{"issue":"10","key":"2023042108445330200_bvad043-B33","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1002\/jbmr.3480","article-title":"Hypocitraturia is an untoward Side effect of synthetic human parathyroid hormone (hPTH) 1-34 therapy in hypoparathyroidism that may increase renal morbidity","volume":"33","author":"Gafni","year":"2018","journal-title":"J Bone Miner Res"},{"issue":"Suppl 1","key":"2023042108445330200_bvad043-B34","doi-asserted-by":"crossref","first-page":"A257","DOI":"10.1210\/jendso\/bvab048.523","article-title":"Change in estimated glomerular filtration rate in adult patients with chronic hypoparathyroidism treated with rhPTH(1-84) compared with a historical control cohort","volume":"5","author":"Ayodele","year":"2021","journal-title":"J Endo Soc"},{"issue":"10","key":"2023042108445330200_bvad043-B35","doi-asserted-by":"crossref","first-page":"e3557","DOI":"10.1210\/clinem\/dgaa490","article-title":"Five-year estimated glomerular filtration rate in patients with hypoparathyroidism treated with and without rhPTH(1-84)","volume":"105","author":"Chen","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"2023042108445330200_bvad043-B36","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1111\/cen.14813","article-title":"The risk of chronic kidney disease development in adult patients with chronic hypoparathyroidism treated with rhPTH(1-84): a retrospective cohort study","volume":"98","author":"Rejnmark","year":"2023","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"5","key":"2023042108445330200_bvad043-B37","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1016\/j.clinthera.2014.04.001","article-title":"Pharmacokinetics and pharmacodynamics of subcutaneous recombinant parathyroid hormone (1-84) in patients with hypoparathyroidism: an open-label, single-dose, phase I study","volume":"36","author":"Clarke","year":"2014","journal-title":"Clin Therap"},{"issue":"1","key":"2023042108445330200_bvad043-B38","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1146\/annurev.med.051308.111339","article-title":"Regulation of phosphate homeostasis by PTH, vitamin D, and FGF23","volume":"61","author":"Bergwitz","year":"2010","journal-title":"Annu Rev Med"},{"issue":"4","key":"2023042108445330200_bvad043-B39","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/j.ecl.2018.07.009","article-title":"Hypoparathyroidism and the kidney","volume":"47","author":"Peacock","year":"2018","journal-title":"Endocrinol Metab Clin North Am"},{"key":"2023042108445330200_bvad043-B40","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000486060","article-title":"Physiology of the calcium-parathyroid hormone-vitamin D axis","volume":"50","author":"Goltzman","year":"2018","journal-title":"Front Horm Res"},{"key":"2023042108445330200_bvad043-B41","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.metabol.2019.06.010","article-title":"New developments in our understanding of vitamin metabolism, action and treatment","volume":"98","author":"Christakos","year":"2019","journal-title":"Metabolism"},{"issue":"10232","key":"2023042108445330200_bvad043-B42","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1016\/S0140-6736(20)30538-9","article-title":"Treating hypoparathyroidism with recombinant human parathyroid hormone (1-34): long-term safety concerns","volume":"395","author":"Goujard","year":"2020","journal-title":"Lancet"},{"issue":"5","key":"2023042108445330200_bvad043-B43","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1359\/jbmr.081233","article-title":"PTH(1-34) replacement therapy in a child with hypoparathyroidism caused by a sporadic calcium receptor mutation","volume":"24","author":"Theman","year":"2009","journal-title":"J Bone Miner Res"},{"issue":"10328","key":"2023042108445330200_bvad043-B44","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/S0140-6736(22)00149-0","article-title":"Calvarial hyperostosis in primary hyperparathyroidism and other settings of increased cAMP signalling","volume":"399","author":"Theng","year":"2022","journal-title":"Lancet"},{"issue":"2","key":"2023042108445330200_bvad043-B45","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1007\/s00198-017-4298-3","article-title":"Serum parathyroid hormone is associated with increased cortical porosity of the inner transitional zone at the proximal femur in postmenopausal women: the Tromso study","volume":"29","author":"Osima","year":"2018","journal-title":"Osteoporos Int"},{"issue":"8","key":"2023042108445330200_bvad043-B46","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1002\/jbmr.1627","article-title":"Daily parathyroid hormone 1-34 replacement therapy for hypoparathyroidism induces marked changes in bone turnover and structure","volume":"27","author":"Gafni","year":"2012","journal-title":"J Bone Miner Res"},{"issue":"4","key":"2023042108445330200_bvad043-B47","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1007\/s11154-020-09614-0","article-title":"Skeletal abnormalities in hypoparathyroidism and in primary hyperparathyroidism","volume":"22","author":"Silva","year":"2020","journal-title":"Rev Endocr Metab Disord"}],"container-title":["Journal of the Endocrine Society"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jes\/advance-article-pdf\/doi\/10.1210\/jendso\/bvad043\/49746648\/bvad043.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jes\/article-pdf\/7\/5\/bvad043\/50052399\/bvad043.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jes\/article-pdf\/7\/5\/bvad043\/50052399\/bvad043.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,21]],"date-time":"2023-04-21T08:45:37Z","timestamp":1682066737000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jes\/article\/doi\/10.1210\/jendso\/bvad043\/7103305"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,6]]},"references-count":47,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,3,6]]}},"URL":"https:\/\/doi.org\/10.1210\/jendso\/bvad043","relation":{},"ISSN":["2472-1972"],"issn-type":[{"value":"2472-1972","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,5,1]]},"published":{"date-parts":[[2023,3,6]]},"article-number":"bvad043"}}